No Data
No Data
Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology
Palvella Says US Patent Granted for Qtorin Gel to Treat Rare Skin Disorder
Palvella Therapeutics: USPTO Issues Patent For Claims Related To Palvella's Product Candidate QTORIN 3.9% Rapamycin Anhydrous Gel
Express News | Palvella Therapeutics Granted Additional U.S. Patent for Qtorin™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
Palvella Therapeutics Independent Chairman of the Board Acquires 1.4% More Stock
Palvella Therapeutics Announces QTORIN Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University's Feinberg School of...